Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Karen Anderson Sells 41,076 Shares of Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Karen Anderson sold 41,076 shares of the business’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the transaction, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,870,000.20. The trade was a 39.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA opened at $28.70 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of -15.68 and a beta of 1.55. The stock has a 50-day moving average of $25.85 and a 200 day moving average of $25.07. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $9.60 and a one year high of $30.58.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in CNTA. Avoro Capital Advisors LLC boosted its stake in Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after purchasing an additional 5,808,080 shares in the last quarter. EcoR1 Capital LLC lifted its stake in shares of Centessa Pharmaceuticals by 466.4% in the 4th quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock valued at $77,906,000 after purchasing an additional 2,565,000 shares during the period. Braidwell LP acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth about $54,730,000. Federated Hermes Inc. acquired a new position in Centessa Pharmaceuticals in the 3rd quarter worth about $42,429,000. Finally, Maverick Capital Ltd. purchased a new position in shares of Centessa Pharmaceuticals during the 4th quarter valued at approximately $41,110,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Wolfe Research assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, February 24th. They set an “outperform” rating and a $40.00 target price for the company. B. Riley Financial upped their price target on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Truist Financial boosted their target price on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $39.80.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.